-
E413691-25mgInformationErvogastat (PF-06865571) is a potent diacylglycerol acyltransferase 2 inhibitor (DGAT2i) that reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
-
E413691-50mgInformationErvogastat (PF-06865571) is a potent diacylglycerol acyltransferase 2 inhibitor (DGAT2i) that reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
-
E413691-5mgInformationErvogastat (PF-06865571) is a potent diacylglycerol acyltransferase 2 inhibitor (DGAT2i) that reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
-
-
-
-
-
E288332-100mgproduct description:ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >:100-fold selectivity over PKA.
-
E288332-10mgproduct description:ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >:100-fold selectivity over PKA.
-
E288332-50mgproduct description:ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >:100-fold selectivity over PKA.
-
E288332-5mgproduct description:ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >:100-fold selectivity over PKA.
-